Samsung Biologics said it has renewed its largest-ever contract manufacturing deal, valued at 2.07 trillion won ($1.4 billion), marking a strong start to 2025.

The Korean contract development and manufacturing organization (CDMO) giant disclosed on Tuesday that it had signed a massive contract with an unnamed European pharmaceutical company. The deal, bound by confidentiality agreements, is set to run through December 2030.

The agreement represents 40 percent of Samsung Biologics' total 2024 order intake of 5.4 trillion won, which was a record-breaking figure at the time.

The announcement comes just three months after the company clinched a 1.7 trillion won deal with an Asian client in October.

Samsung Biologics continues to grow its presence in key markets such as the U.S., Europe, and Asia. In 2024 alone, the company signed three deals valued at over 1 trillion won each. The company's cumulative order volume since its founding has now surpassed $17.6 billion, supported by strong relationships with 17 of the world’s top 20 pharmaceutical companies.

Meanwhile, Samsung Biologics is actively engaging with potential clients and investors at high-profile events, including the most recent 2025 J.P. Morgan Healthcare Conference, the largest investment gathering in the global pharmaceutical and biotechnology industry, held in San Francisco from Monday to Thursday.

“Our relentless commitment to operational excellence, regulatory compliance, and customer satisfaction underpins our record-breaking performance,” Samsung Biologics CEO John Rim said. “We will continue to expand our capabilities and forge strong partnerships to meet the growing demand for biopharmaceuticals globally.”